2 3

Cited 0 times in

Cited 0 times in

Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab

Authors
 Jeon, So Yeon  ;  Wang, Sheng-Min  ;  Roh, Hyun Woong  ;  Kim, Keun You  ;  Chang, Yoon Young  ;  Kim, Eosu  ;  Bae, Jae-Nam  ;  Ryu, Seung-Ho 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.40(28), 2025-07 
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN
 1011-8934 
Issue Date
2025-07
MeSH
Aged ; Alzheimer Disease* / drug therapy ; Alzheimer Disease* / pathology ; Amyloid beta-Peptides / antagonists & inhibitors ; Amyloid beta-Peptides / immunology ; Antibodies, Monoclonal / therapeutic use ; Antibodies, Monoclonal, Humanized* / therapeutic use ; Humans ; Republic of Korea
Keywords
Lecanemab ; Donanemab ; Practical Guide ; Appropriate Use ; Antiamyloid Monoclonal Antibodies ; Alzheimer&apos ; s Disease
Abstract
The advent of anti-amyloid monoclonal antibody (mAb) therapies represents a paradigm shift in the treatment of Alzheimer's disease (AD), from symptomatic relief to disease modification. Lecanemab, a humanized mAb targeting soluble A beta protofibrils and plaque, received regulatory approval in Korea in July 2024, following global randomized controlled trial data demonstrating its efficacy to reduce amyloid burden and slow cognitive decline. However, the introduction of such therapies into routine clinical realm presents several practical and systemic challenges, particularly in the context of Korea's unique healthcare infrastructure and reimbursement environment. In response, the Korean Association for Geriatric Psychiatry has developed the first comprehensive domestic guidance to facilitate the safe, evidence-based, and patient-centered use of anti-amyloid mAb therapies, first focused on lecanemab. This practical guide goes beyond simple eligibility criteria. It provides detailed recommendations on clinical and imaging-based candidate selection, amyloidrelated imaging abnormalities (ARIA) risk stratification and monitoring protocols, infusion workflows, adverse event management strategies, and multidisciplinary coordination within hospital systems. It also emphasizes shared decision-making and outlines how to navigate situations where treatment is not appropriate, such as in patients with advanced dementia, high-risk magnetic resonance imaging findings, or poor treatment adherence, reinforcing that non-treatment can also represent a legitimate, evidence-based clinical decision. The guidance further highlights the urgent need to generate real-world data that reflect the treatment experiences of Korean patients. Multicenter collaboration will be essential for collecting data on adherence rates, ARIA incidence, cognitive outcomes, and functional trajectories, which in turn can inform policy decisions, insurance reimbursement models, and future updates to clinical guidelines. This publication represents the first nationwide roadmap in Korea to support clinicians in the appropriate integration of monoclonal antibody therapies for AD. By combining scientific rigor, operational feasibility, and ethical sensitivity, it aims to promote safe and responsible adoption of disease-modifying treatment across various clinical settings.
Files in This Item:
89523.pdf Download
DOI
10.3346/jkms.2025.40.e215
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Eosu(김어수) ORCID logo https://orcid.org/0000-0001-9472-9465
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/207361
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links